

Continuing Education

Guidelines Updates: Venous Thromboembolism, American Diabetes Association, Opioids, and Beers Criteria

Authors:

Katherine Fuller
Pharm.D., 2016
Harrison School of Pharmacy, Auburn University

Sarah Summers
Pharm.D., 2016
Harrison School of Pharmacy, Auburn University

Justin Smothers
Pharm.D., 2016
Harrison School of Pharmacy, Auburn University

Corresponding Author:

Wesley Lindsey, Pharm.D.
Associate Clinical Professor
Drug Information and Learning Resource Center
Harrison School of Pharmacy, Auburn University

Universal Activity #: 0178-0000-16-105-H04-P | 1.25 contact hours (.125 CEUs)

Initial Release Date: November 28, 2016 | Expires: March 31, 2019

QUIZ – GUIDELINES UPDATES | ACPE#: 0178-0000-16-105-H04-P

1. Which of the following is not a first-line option for the long-term treatment of VTE (DVT or PE)?
 - a. Warfarin
 - b. Apixaban
 - c. Dabigatran
 - d. Rivaroxaban
 - e. Edoxaban
 2. Aspirin should be given for recurrent VTE prevention in a patient refusing to continue anticoagulation therapy for an unprovoked proximal VTE.
 - a. True
 - b. False
 3. If a patient experiences a recurrent VTE on LMWH, what percentage should LMWH be increased by?
 - a. 15-20%
 - b. 25-33%
 - c. 50%
 4. What is the first-line treatment for VTE in cancer (ie cancer induced thrombosis)?
 - a. Warfarin
 - b. Rivaroxaban
 - c. LMWH
 5. A patient presenting with an acute PE without hypotension should generally be given a thrombolytic agent.
 - a. True
 - b. False
 6. At what age should all adults be screened for diabetes regardless of weight?
 - a. 40
 - b. 65
 - c. 45
 - d. 30
 7. Ezetimibe can be added to a moderate-intensity statin to provide additional cardiovascular benefits in certain individuals with diabetes.
 - a. True
 - b. False
 8. At what age should an initial fasting lipid panel be done in children?
 - a. 2
 - b. 6
 - c. 8
 - d. 10
 9. 6 – 6.5% is the new target A1c during pregnancy.
 - a. True
 - b. False
 10. The term diabetic may still be used to define individuals with diabetes.
 - a. True
 - b. False
 11. Which of the following most appropriately defines “chronic pain”?
 - a. Pain which continues or is expected to continue for more than 3 months or past the time of normal healing.
 - b. Pain which continues or is expected to continue for more than 1 month or past the time of normal healing.
 - c. Pain which continues or is expected to continue for more than 1 week or past the time of normal healing.
 - d. Pain which continues or is expected to continue for more than 3 weeks or past the time of normal healing.
 12. When prescribing opioid therapy, physicians should avoid exceeding ___ morphine milligram equivalents (MME) per day.
 - a. 50
 - b. 75
 - c. 90
 - d. 120
-

QUIZ – GUIDELINES UPDATES | ACPE#: 0178-0000-16-105-H04-P

13. When prescribing opioids for acute pain, which of these days supply is generally considered too many?
 - a. 14
 - b. 7
 - c. 5
 - d. 3

 14. The Prescription drug monitoring program (PDMP) should be reviewed a minimum of:
 - a. Every 6 months
 - b. Every year
 - c. Every 3 months
 - d. Every 2 years

 15. When tapering opioid therapy, it is generally recommended to decrease the opioid dose by:
 - a. 50% per week
 - b. 10% per week
 - c. 10% per day
 - d. 50% per day

 16. Which 2 NSAIDs are inappropriate to use in the geriatric population?
 - a. Indomethacin and ketorolac
 - b. Ibuprofen and naproxen
 - c. Indomethacin and ibuprofen
 - d. Ketorolac and ibuprofen

 17. Aripiprazole, quetiapine and clozapine can be used when treating a geriatric patient with Parkinson's Disease?
 - a. True
 - b. False

 18. How many CNS active drugs can be used simultaneously in geriatric patients?
 - a. 1
 - b. 2
 - c. 3
 - d. 4

 19. At what CrCl should edoxaban be avoided in geriatric patients?
 - a. 30-50 mL/min
 - b. <30 mL/min or >95 mL/min
 - c. <30 ml/min
 - d. <60 ml/min
-

Participant Information:

AL License # _____

Name _____

Address _____

City _____ State _____ Zip _____

E-mail _____

NABP e-Profile # _____

MM/DD (month/day of birth) _____

How long did it take you to read the article and complete this test?

_____ hours _____ minutes

My signature certifies that I have independently taken this CE examination.

CE Assessment Answers

Please circle your answers (one answer per question)

1.	A	B	C	D	E
2.	A	B			
3.	A	B	C		
4.	A	B	C		
5.	A	B			
6.	A	B	C	D	
7.	A	B			
8.	A	B	C	D	
9.	A	B			
10.	A	B			
11.	A	B	C	D	
12.	A	B	C	D	
13.	A	B	C	D	
14.	A	B	C	D	
15.	A	B	C	D	
16.	A	B	C	D	
17.	A	B			
18.	A	B	C	D	
19.	A	B	C	D	

Program Evaluation – Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- | | | | | |
|-----------------------------------|---|---|---|---|
| 1. Overall quality of the article | 1 | 2 | 3 | 4 |
| 2. Relevance to pharmacy practice | 1 | 2 | 3 | 4 |
| 3. Value of the content | 1 | 2 | 3 | 4 |

Please answer each question, marking whether you agree or disagree.

4. This course met the learning objectives. Agree Disagree
5. The article did not promote a particular product or company. Yes No

Impact of the Activity

The information presented (check all that apply):

6. Reinforced my current practice/treatment habits Will improve my practice/patient outcomes
 Provided new ideas or information I expect to use Adds to my knowledge
7. Will the information presented cause you to make any changes in how you do your job? Yes No
8. How committed are you to making these changes?
 (Not committed) 1 2 3 4 (Very committed).
9. Do you feel future activities on this subject matter are necessary and/or important? Yes No

Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

Yes No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.